Annual Meeting Program - Society of Toxicology

Society of Toxicology 2008
Program Description (Continued)
Abstract #
into various facets of a successful career in toxicology. 2. To highlight qualities
necessary to develop these career characteristics. 3. To provide a path
forward towards developing a career as an academic, industrial or entrepreneurial
toxicologist. This session will have three parallel components.
Firstly, it will be targeted towards the career development of early career
toxicologists including graduate students, postdoctoral fellows and young
investigators who are at the crossroads of deciding a suitable path forward
in toxicological sciences. The presentation will give an in-depth perspective
about career as an industrial toxicologist, toxicologist in drug development,
academic toxicologist, clinical toxicologist, forensic toxicologist, ecotoxicologist,
regulatory toxicologist, or occupational toxicologist. The second
component is targeted towards educating the toxicologists about developing
adequate skill set necessary to manage a laboratory in academics or in
industry and secondly towards applying for potential funding opportunities
to support the laboratory. The third component is geared towards an entrepreneurial
toxicologist desiring to start a company at any stage of his/her
career. This presentation will lay out different steps involved from having
the initial idea to starting a company, including approaching the venture
capitalist, strategy design, implementation and execution, etc.
#664 9:00 PROFESSIONAL CAREER DEVELOPMENT
AS TOXICOLOGIST. V. S. Vaidya 1 , D. A. Keller 2 ,
J. Popp 3 , V. McGovern 4 , P. J. Mastin 5 and S. B. Farr 6 .
1
Medicine-Renal, Brigham and Women’s Hospital,
Harvard Medical School, Boston, MA, 2 Sanofi-
Aventis, Malvern, PA, 3 Stratoxon LLC, Lancaster,
PA, 4 Burroughs Wellcome Fund, Research Triangle
Park, NC, 5 NIEHS, Research Triangle Park, NC and
6
Vista Therapeutics, Santa Fe, NM.
#665 9:05 CAREERS IN TOXICOLOGY. J. Popp.
Stratoxon LLC, Lancaster, PA.
#666 9:45 MANAGING A LABORATORY. V. McGovern.
Burroughs Wellcome Fund, Research Triangle Park,
NC. Sponsor: V. Vaidya.
#667 10:25 NIH GRANT OPPORTUNITIES IN
TOXICOLOGY. P. J. Mastin. NIEHS, Research
Triangle Park, NC. Sponsor: V. Vaidya.
#668 11:05 STARTING A COMPANY. S. B. Farr. Vista
Therapeutics, Santa Fe, NM. Sponsor: V. Vaidya.
Tuesday Morning, March 18
9:00 AM to 11:45 AM
Room 6C
PLATFORM SESSION: ACCELERATING DISCOVERIES IN
TOXICOLOGY THROUGH ‘OMICS RESEARCH
Chairperson(s): Helmut Zarbl, University of Medicine and Dentistry of
New Jersey, Piscataway, NJ.
#669 9:00 A NOVEL METHOD FOR DERIVING
MECHANISTICALLY-ANCHORED GENE
EXPRESSION BIOMARKERS. R. J. Brennan,
W. Shi, A. Bugrim, Y. Nikolsky and T. Nikolskya.
GeneGo Inc, San Diego, CA.
#670 9:21 INDEPENDENTLY PUBLIC
TOXICOGENOMICS STUDIES VALIDATE
THE TRANSSULFUATION PATHWAY AS
POTENTIAL LIVER TOXICITY PATHWAY.
M. Chen 1,2 , L. K. Schnackenberg 1 , R. Holland 1 ,
R. D. Beger 1 , S. Isukapalli 2 , P. G. Georgopoulos 2 ,
W. J. Welsh 2 and W. Tong 1 . 1 Division of Systems
Toxicology, FDA’s National center for toxicology
research, Jefferson, AR and 2 Departments
of Pharmacology and of Environmental and
Occupational Medicine, UMDNJ-RWJMS,
Piscataway, NJ.
Abstract #
#671 9:42 PHENOTYPIC ANCHORING OF
CARCINOGEN-INDUCED GENE
EXPRESSION REVEALS A COINCIDENCE
BETWEEN THE NO TRANSCPTIONAL
EFFECT LEVEL (NOTEL) AND THE NO
DETECTABLE ADDUCT LEVEL (NODAL):
IMPLICATIONS FOR RISK ASSESSMENT?
H. Zarbl 1 , R. C. Sullivan 1 , J. Glick 2 and P. Vouros 2 .
1
Environmental And Occupational Health Sciences
Institute, Robert Wood Johnson Medical School,
UMDNJ, Piscataway, NJ and 2 Department of
Chemistry and Chemical Biology and The Barnett
Institute, Northeastern University, Boston, MA.
#672 10:03 TRANSCRIPT PROFILING REVEALS
DIVERGENT REGULATION OF
MITOCHONDRIAL METABOLISM IN
HUMAN AND MOUSE MODELS IN
RESPONSE TO XENOBIOTICS. K. M.
Olsavsky 1 , M. Johnson 1 , S. Strom 2 , H. Zarbl 3 and
C. Omiecinski 1 . 1 Department of Veterinary and
Biomedical Sciences, Pennsylvania State University,
University Park, PA, 2 Department of Pathology,
University of Pittsburgh, Pittsburgh, PA and 3 Fred
Hutchinson Cancer Research Center, Seattle, WA.
#673 10:24 DIFFERENCES IN GENE EXPRESSION
PROFILES FROM TCDD-, 4-PECDF- OR
TCDF-TREATED PRIMARY RAT AND
HUMAN HEPATOCYTES. J. Rowlands 1 , R. A.
Budinsky 1 , B. Gollapudi 1 , D. Boverhof 1 , S. Ferguson 3 ,
R. F. Novak 2 , D. Cukovic 2 , S. Salagrama 2 and A.
Dombkowski 2 . 1 The Dow Chemical Company,
Midland, MI, 2 Institute of Environmental Health
Sciences, Detroit, MI and 3 CellzDirect, Inc.,
Pittsboro, NC.
#674 10:45 COMPARATIVE METABOLOMIC ANALYSIS
OF HEPATOTOXICITY EXPERIMENTS IN
RATS AND MICE. G. L. Jahns 1 , N. V. Reo 2 , M. N.
Kent 2 , M. K. Makley 2 , A. Kopec 3 , D. R. Boverhof 3 ,
L. Burgoon 3 , T. R. Zacharewski 3 and N. DelRaso 4 .
1
Advanced Information Technologies, BAE Systems,
San Diego, CA, 2 Department Biochemistry &
Molecular Biology, Boonshoft School of Medicine,
Wright State University, Dayton, OH, 3 Department
Biochemistry & Molecular Biology, National
Food Safety & Toxicology Center, Michigan
State University, East Lansing, MI and 4 Human
Effectiveness Directorate, Air Force Research
Laboratory, Wright-Patterson AFB, OH.
#675 11:05 APPLICATION OF A SYSTEMS
TOXICOLOGY APPROACH TO
INVESTIGATE TROGLITAZONE
HEPATOTOXICITY IN THE RAT. E. Troesken 1 ,
A. Gruhler 2 , E. Boitier 1 , J. Marchandeau 1 , K.
Arnold 3 , B. Bidlingmaier 1 , A. Brandenburg 4 ,
M. Kurz 1 , A. Pfenninger 1 , J. Schnieders 1 , I.
Stammberger 1 , M. Stolte 1 and A. Amberg 1 . 1 Sanofi-
Aventis, Hattersheim, Germany, 2 Novo Nordisk
A/S, Bagsværd, Denmark, 3 Boehringer Ingelheim
Pharmacology GmbH & Co KG, Biberach, Germany
and 4 Genedata AG, Basel, Switzerland. Sponsor: M.
Bonnefoi.
Tuesday
up-to-date information at www.toxicology.org 149